GT Biopharma (GTBP) Change in Cash (2010 - 2026)

GT Biopharma (GTBP) has reported Change in Cash for 17 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 233.17% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $6.6 million (up 1191.14% YoY), while the FY2025 annual figure was $2.9 million, down 3.51% from the prior year.
• Change in Cash fell to $2.1 million in Q1 2026 per GTBP's latest filing, from $4.3 million in the prior quarter.
• Across five years, Change in Cash topped out at $7.3 million in Q2 2024 and bottomed at -$3.6 million in Q1 2023.
• Historically, Change in Cash has averaged $2882.4 across 5 years, with a median of -$1.6 million in 2023.
• On a YoY basis, Change in Cash climbed as much as 910.94% in 2024 and fell as far as 2200.84% in 2024.
• GT Biopharma's Change in Cash stood at $3.2 million in 2022, then sank by 148.92% to -$1.6 million in 2023, then slumped by 57.23% to -$2.5 million in 2024, then soared by 273.65% to $4.3 million in 2025, then plunged by 50.7% to $2.1 million in 2026.
• Business Quant data shows GTBP's Change in Cash at $2.1 million in Q1 2026, $4.3 million in Q4 2025, and -$2.7 million in Q3 2025.